Metabolic syndrome and rare gynecological cancers in the Metabolic syndrome and Cancer project (Me-Can)
2011 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 22, no 6, 1339-1345 p.Article in journal (Refereed) Published
BACKGROUND: Risk factors for rare gynecological cancers are largely unknown. Initial research has indicated that the metabolic syndrome (MetS) or individual components could play a role. Materials and methods: The Metabolic syndrome and Cancer project cohort includes 288 834 women. During an average follow-up of 11 years, 82 vulvar, 26 vaginal and 43 other rare gynecological cancers were identified. Hazard ratios (HRs) were estimated fitting Cox proportional hazards regression models for tertiles and standardized z-scores [with a mean of 0 and a standard deviation (SD) of 1] of body mass index (BMI), blood pressure, glucose, cholesterol, triglycerides and MetS. Risk estimates were corrected for random error in the measurement of metabolic factors. RESULTS: The MetS was associated with increased risk of vulvar [HR 1.78, 95% confidence interval (CI) 1.30-2.41) and vaginal cancer (HR 1.87, 95% CI 1.07-3.25). Among separate MetS components, 1 SD increase in BMI was associated with overall risk (HR 1.43, 95% CI 1.23-1.66), vulvar (HR 1.36, 95% CI 1.11-1.69) and vaginal cancer (HR 1.79, 95% CI 1.30-2.46). Blood glucose and triglyceride concentrations were associated with increased risk of vulvar cancer (HR 1.98, 95% CI 1.10-3.58 and HR 2.09, 95% CI 1.39-3.15, respectively). CONCLUSION: The results from this first prospective study on rare gynecological cancers suggest that the MetS and its individual components may play a role in the development of these tumors.
Place, publisher, year, edition, pages
Oxford Journals , 2011. Vol. 22, no 6, 1339-1345 p.
epidemiology, MetS, rare gynecological cancers
Cancer and Oncology
Research subject Oncology
IdentifiersURN: urn:nbn:se:umu:diva-42228DOI: 10.1093/annonc/mdq597PubMedID: 20966183OAI: oai:DiVA.org:umu-42228DiVA: diva2:408947